Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)

BackgroundBromonitrozidine (RRx-001) is a minimally toxic, NLRP3 inhibitor that has been observed, in experimental systems, to also downregulate CD47, repolarize tumor associated macrophages (TAMs) and normalize aberrant tumor perfusion. This phase 1 pilot study was undertaken to determine the safet...

Full description

Bibliographic Details
Main Authors: Tony Reid, Bryan Oronsky, Scott Caroen, Mary Quinn, Jeannie Williams, Pedro Cabrales, Nacer Abrouk
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
RRx-001
CD-47
tumor associated macrophage
vascular normalization
nivolumab
cold tumors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1104753/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1104753/full

Similar Items